polyclonal bk antibodies Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • rabbit anti dsred  (TaKaRa)
    99
    TaKaRa rabbit anti dsred
    Rabbit Anti Dsred, supplied by TaKaRa, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti dsred/product/TaKaRa
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti dsred - by Bioz Stars, 2023-09
    99/100 stars
    		  Buy from Supplier
    opg rabbit anti human polyclonal antibody  (Cusabio)
    93
    Cusabio opg rabbit anti human polyclonal antibody
    Opg Rabbit Anti Human Polyclonal Antibody, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/opg rabbit anti human polyclonal antibody/product/Cusabio
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    opg rabbit anti human polyclonal antibody - by Bioz Stars, 2023-09
    93/100 stars
    		  Buy from Supplier
    anti influenza a  (TaKaRa)
    93
    TaKaRa anti influenza a
    Anti Influenza A, supplied by TaKaRa, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti influenza a/product/TaKaRa
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti influenza a - by Bioz Stars, 2023-09
    93/100 stars
    		  Buy from Supplier
    rrid ab 2209751 zsgreen clontech  (TaKaRa)
    94
    TaKaRa rrid ab 2209751 zsgreen clontech
    Rrid Ab 2209751 Zsgreen Clontech, supplied by TaKaRa, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rrid ab 2209751 zsgreen clontech/product/TaKaRa
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rrid ab 2209751 zsgreen clontech - by Bioz Stars, 2023-09
    94/100 stars
    		  Buy from Supplier
    ehmt2 csb pa007497ga01hu antibodies  (Cusabio)
    90
    Cusabio ehmt2 csb pa007497ga01hu antibodies
    <t>EHMT2</t> is overexpressed in breast cancer (BRC). (A) Heatmap of gene expression related to histone methylation/demethylation in the in silico histone methyltransferase/demethylase panel, sorted by fold change in the BRC/normal FPKM value. In the heatmap, yellow indicates normal liver samples, while red indicates BRC samples in TCGA. The threshold was set to a 2.0-fold-change. (B) Expression levels of EHMT2 in BRC using normal and BRC samples. P-values were calculated using Wilcoxon’s tests ( *** P<0.001). (C) Immunohistochemical analysis of EHMT2 in a BRC tissue microarray. Breast cancer tissues were purchased from BioChain. Scale bar, 200 µ m. (D) Cell growth assay. After knocking down EHMT2 for 72 h, RT-qPCR analysis of EHMT2 was performed. Actin (ACTB) was used as the internal control (left panel). Cell fixation with 100% methanol and cell staining with crystal violet was performed. Scale bar, 100 µ m (right panel); siRNA duplexes against EHMT2 (siEHMT2; 5′-GCAAAUAUUUCACCUGCCATT-3′, 5′-UGGCAGGUGAAAUAUUUGCTT-3′) were purchased from ST Pharm. Negative control siRNA was also used (siCont; 5′-AUGAACGUGAAUUGCUCAATT-3′, 5′-UUGAGCAAUUCACGUUCACTT-3′). (E) Western blot analysis of EHMT2, PARP, caspase-3 and β-catenin. ACTB was used as the internal control. (F) Spheroid formation. MCF7 cells treated with siEHMT2 and siCont were loaded onto a spheroid plate and incubated for 96 h. The cells were imaged under a microscope. Scale bar, 500 µ m.
    Ehmt2 Csb Pa007497ga01hu Antibodies, supplied by Cusabio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ehmt2 csb pa007497ga01hu antibodies/product/Cusabio
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ehmt2 csb pa007497ga01hu antibodies - by Bioz Stars, 2023-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    EHMT2 is overexpressed in breast cancer (BRC). (A) Heatmap of gene expression related to histone methylation/demethylation in the in silico histone methyltransferase/demethylase panel, sorted by fold change in the BRC/normal FPKM value. In the heatmap, yellow indicates normal liver samples, while red indicates BRC samples in TCGA. The threshold was set to a 2.0-fold-change. (B) Expression levels of EHMT2 in BRC using normal and BRC samples. P-values were calculated using Wilcoxon’s tests ( *** P<0.001). (C) Immunohistochemical analysis of EHMT2 in a BRC tissue microarray. Breast cancer tissues were purchased from BioChain. Scale bar, 200 µ m. (D) Cell growth assay. After knocking down EHMT2 for 72 h, RT-qPCR analysis of EHMT2 was performed. Actin (ACTB) was used as the internal control (left panel). Cell fixation with 100% methanol and cell staining with crystal violet was performed. Scale bar, 100 µ m (right panel); siRNA duplexes against EHMT2 (siEHMT2; 5′-GCAAAUAUUUCACCUGCCATT-3′, 5′-UGGCAGGUGAAAUAUUUGCTT-3′) were purchased from ST Pharm. Negative control siRNA was also used (siCont; 5′-AUGAACGUGAAUUGCUCAATT-3′, 5′-UUGAGCAAUUCACGUUCACTT-3′). (E) Western blot analysis of EHMT2, PARP, caspase-3 and β-catenin. ACTB was used as the internal control. (F) Spheroid formation. MCF7 cells treated with siEHMT2 and siCont were loaded onto a spheroid plate and incubated for 96 h. The cells were imaged under a microscope. Scale bar, 500 µ m.

    Journal: International Journal of Oncology

    Article Title: The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer

    doi: 10.3892/ijo.2018.4608

    Figure Lengend Snippet: EHMT2 is overexpressed in breast cancer (BRC). (A) Heatmap of gene expression related to histone methylation/demethylation in the in silico histone methyltransferase/demethylase panel, sorted by fold change in the BRC/normal FPKM value. In the heatmap, yellow indicates normal liver samples, while red indicates BRC samples in TCGA. The threshold was set to a 2.0-fold-change. (B) Expression levels of EHMT2 in BRC using normal and BRC samples. P-values were calculated using Wilcoxon’s tests ( *** P<0.001). (C) Immunohistochemical analysis of EHMT2 in a BRC tissue microarray. Breast cancer tissues were purchased from BioChain. Scale bar, 200 µ m. (D) Cell growth assay. After knocking down EHMT2 for 72 h, RT-qPCR analysis of EHMT2 was performed. Actin (ACTB) was used as the internal control (left panel). Cell fixation with 100% methanol and cell staining with crystal violet was performed. Scale bar, 100 µ m (right panel); siRNA duplexes against EHMT2 (siEHMT2; 5′-GCAAAUAUUUCACCUGCCATT-3′, 5′-UGGCAGGUGAAAUAUUUGCTT-3′) were purchased from ST Pharm. Negative control siRNA was also used (siCont; 5′-AUGAACGUGAAUUGCUCAATT-3′, 5′-UUGAGCAAUUCACGUUCACTT-3′). (E) Western blot analysis of EHMT2, PARP, caspase-3 and β-catenin. ACTB was used as the internal control. (F) Spheroid formation. MCF7 cells treated with siEHMT2 and siCont were loaded onto a spheroid plate and incubated for 96 h. The cells were imaged under a microscope. Scale bar, 500 µ m.

    Article Snippet: The samples were stained with anti-HSPD1 (#12165S), poly(ADP-ribose) polymerase (PARP; #9542S) and caspase-3 (#9662S) antibodies from Cell Signaling Technology, Inc. (Danvers, MA, USA), EHMT2 (CSB-PA007497GA01HU) antibodies from Cusabio and ACTB (SC-47778) antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), at 4°C (overnight).

    Techniques: Expressing, Methylation, In Silico, Immunohistochemical staining, Microarray, Growth Assay, Quantitative RT-PCR, Staining, Negative Control, Western Blot, Incubation, Microscopy

    EHMT2 expression and breast cancer (BRC) prognosis. (A) Expression of EHMT2 in patients with BRC from the UNC500 cohort. The median value of EHMT2 expression was considered the cut-off in the patient cohort. (B and C) Kaplan-Meier curves of (B) overall survival and (C) recurrence-free survival in the UNC500 cohort. (D and E) Kaplan-Meier curves of (D) overall survival and (E) metastasis-free survival in the KFSYSCC cohort.

    Journal: International Journal of Oncology

    Article Title: The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer

    doi: 10.3892/ijo.2018.4608

    Figure Lengend Snippet: EHMT2 expression and breast cancer (BRC) prognosis. (A) Expression of EHMT2 in patients with BRC from the UNC500 cohort. The median value of EHMT2 expression was considered the cut-off in the patient cohort. (B and C) Kaplan-Meier curves of (B) overall survival and (C) recurrence-free survival in the UNC500 cohort. (D and E) Kaplan-Meier curves of (D) overall survival and (E) metastasis-free survival in the KFSYSCC cohort.

    Article Snippet: The samples were stained with anti-HSPD1 (#12165S), poly(ADP-ribose) polymerase (PARP; #9542S) and caspase-3 (#9662S) antibodies from Cell Signaling Technology, Inc. (Danvers, MA, USA), EHMT2 (CSB-PA007497GA01HU) antibodies from Cusabio and ACTB (SC-47778) antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), at 4°C (overnight).

    Techniques: Expressing

    RNA-seq analysis after siEHMT2 treatment. (A) Functional enrichment analysis of RNA-seq EHMT2 knockdown results obtained from the Ingenuity Pathway Knowledge Base. (B) Gene Ontology (GO) pathway term enrichment networks. GO pathway term networks in the EHMT2 knockdown and control groups were functionally grouped by ClueGO (top panel). The Venn diagram shows the distribution of the functionally grouped GO terms (bottom panel). Terms in the functionally grouped networks were cut-off at P<0.05.

    Journal: International Journal of Oncology

    Article Title: The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer

    doi: 10.3892/ijo.2018.4608

    Figure Lengend Snippet: RNA-seq analysis after siEHMT2 treatment. (A) Functional enrichment analysis of RNA-seq EHMT2 knockdown results obtained from the Ingenuity Pathway Knowledge Base. (B) Gene Ontology (GO) pathway term enrichment networks. GO pathway term networks in the EHMT2 knockdown and control groups were functionally grouped by ClueGO (top panel). The Venn diagram shows the distribution of the functionally grouped GO terms (bottom panel). Terms in the functionally grouped networks were cut-off at P<0.05.

    Article Snippet: The samples were stained with anti-HSPD1 (#12165S), poly(ADP-ribose) polymerase (PARP; #9542S) and caspase-3 (#9662S) antibodies from Cell Signaling Technology, Inc. (Danvers, MA, USA), EHMT2 (CSB-PA007497GA01HU) antibodies from Cusabio and ACTB (SC-47778) antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), at 4°C (overnight).

    Techniques: RNA Sequencing Assay, Functional Assay

    EHMT2 controls the expression and subcellular localization of HSPD1. (A) Phosphor array with the lysates of cells in which EHMT2 was knocked down. The phosphor array (ARY003B) was purchased from R&D Biosystems. Approximately 200 µ g of cell lysate was used. (B and C) Expression levels of HSPD1 in breast cancer samples (TCGA); P-values were calculated using Wilcoxon’s tests ( *** P<0.001) (B) and RNA-seq results (C). (D) RT-qPCR analysis of HSPD1 after EHMT2 knockdown in MDA-MB-231 cell lines. ACTB was used as the internal control (top panel). Western blot analysis was performed using the indicated antibodies (bottom panel). (E) Cell growth assay. After knocking down HSPD1 for 72 h, the cells were fixed with 100% methanol and stained with crystal violet. Scale bar, 200 μm (top panel); P-values were calculated using Student’s t-tests ( ** P<0.01) (bottom panel). (F) Western blot analysis after HSPD1 knockdown using anti-HSPD1, anti-PARP, anti-caspase3 and anti-β-catenin antibodies. ACTB was used as the internal control in MB231 cells. (G) Immunocytochemical analysis of HSPD1. MB231 cells treated with siCont or siEHMT2 were fixed with 100% methanol and stained with anti-HSPD1 (Alexa Fluor 488, green) and DAPI (blue). Scale bar, 200 µ m. (H) Cell growth assay. After MB231 cells were treated with BIX01294 for 24 h, the cells were fixed with 100% methanol and stained with crystal violet. Scale bar, 200 μm (top panel); P-values were calculated using Student’s t-tests ( ** P<0.01). (I) RT-qPCR analysis of HSPD1 after treatment with BIX01294. ACTB was used as the internal control (top panel), and the signal intensities corresponding to HSPD1 were quantified using ImageJ software (bottom panel). The P-values were calculated using Student’s t-test ( ** P<0.01). (J) Western blot analysis after treatment with BIX01294 using anti-HSPD1, anti-PARP, anti-caspase3 and anti-β-catenin antibodies. ACTB was used as the internal control in MB231 cells.

    Journal: International Journal of Oncology

    Article Title: The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer

    doi: 10.3892/ijo.2018.4608

    Figure Lengend Snippet: EHMT2 controls the expression and subcellular localization of HSPD1. (A) Phosphor array with the lysates of cells in which EHMT2 was knocked down. The phosphor array (ARY003B) was purchased from R&D Biosystems. Approximately 200 µ g of cell lysate was used. (B and C) Expression levels of HSPD1 in breast cancer samples (TCGA); P-values were calculated using Wilcoxon’s tests ( *** P<0.001) (B) and RNA-seq results (C). (D) RT-qPCR analysis of HSPD1 after EHMT2 knockdown in MDA-MB-231 cell lines. ACTB was used as the internal control (top panel). Western blot analysis was performed using the indicated antibodies (bottom panel). (E) Cell growth assay. After knocking down HSPD1 for 72 h, the cells were fixed with 100% methanol and stained with crystal violet. Scale bar, 200 μm (top panel); P-values were calculated using Student’s t-tests ( ** P<0.01) (bottom panel). (F) Western blot analysis after HSPD1 knockdown using anti-HSPD1, anti-PARP, anti-caspase3 and anti-β-catenin antibodies. ACTB was used as the internal control in MB231 cells. (G) Immunocytochemical analysis of HSPD1. MB231 cells treated with siCont or siEHMT2 were fixed with 100% methanol and stained with anti-HSPD1 (Alexa Fluor 488, green) and DAPI (blue). Scale bar, 200 µ m. (H) Cell growth assay. After MB231 cells were treated with BIX01294 for 24 h, the cells were fixed with 100% methanol and stained with crystal violet. Scale bar, 200 μm (top panel); P-values were calculated using Student’s t-tests ( ** P<0.01). (I) RT-qPCR analysis of HSPD1 after treatment with BIX01294. ACTB was used as the internal control (top panel), and the signal intensities corresponding to HSPD1 were quantified using ImageJ software (bottom panel). The P-values were calculated using Student’s t-test ( ** P<0.01). (J) Western blot analysis after treatment with BIX01294 using anti-HSPD1, anti-PARP, anti-caspase3 and anti-β-catenin antibodies. ACTB was used as the internal control in MB231 cells.

    Article Snippet: The samples were stained with anti-HSPD1 (#12165S), poly(ADP-ribose) polymerase (PARP; #9542S) and caspase-3 (#9662S) antibodies from Cell Signaling Technology, Inc. (Danvers, MA, USA), EHMT2 (CSB-PA007497GA01HU) antibodies from Cusabio and ACTB (SC-47778) antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), at 4°C (overnight).

    Techniques: Expressing, RNA Sequencing Assay, Quantitative RT-PCR, Western Blot, Growth Assay, Staining, Software

    Gene expression pattern of the EHMT2 signature and patient survival of two clusters from the UNC500, KFSYSCC and TCGA cohorts (n=388, 327 and 775, respectively). Follow-up time and survival data were used in this analysis. (A) Gene expression patterns of EHMT2 and its associated genes in the UNC500 cohort. A total of 1,765 genes having at least a 2-fold difference between siEHMT2 and siCont cells were involved in the EHMT2 signature. Among these genes, 1,410 were used in the hierarchical clustering analysis of the UNI500 cohort. The patients were divided into 2 groups: an EHMT2 -low cluster group (ELC) and an EHMT2 -high cluster group (EHC). (B and C) Kaplan-Meier plot depicting (B) overall and (C) recurrence-free survival rates. The survival rates of the patients in the EHC group were significantly increased compared with those of the patients in the ELC group (each P<0.05 as determined by log-rank test). (D-G) Several survival rates of the two patient subgroups in the (D and E) KFSYSCC and (F and G) TCGA cohorts.

    Journal: International Journal of Oncology

    Article Title: The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer

    doi: 10.3892/ijo.2018.4608

    Figure Lengend Snippet: Gene expression pattern of the EHMT2 signature and patient survival of two clusters from the UNC500, KFSYSCC and TCGA cohorts (n=388, 327 and 775, respectively). Follow-up time and survival data were used in this analysis. (A) Gene expression patterns of EHMT2 and its associated genes in the UNC500 cohort. A total of 1,765 genes having at least a 2-fold difference between siEHMT2 and siCont cells were involved in the EHMT2 signature. Among these genes, 1,410 were used in the hierarchical clustering analysis of the UNI500 cohort. The patients were divided into 2 groups: an EHMT2 -low cluster group (ELC) and an EHMT2 -high cluster group (EHC). (B and C) Kaplan-Meier plot depicting (B) overall and (C) recurrence-free survival rates. The survival rates of the patients in the EHC group were significantly increased compared with those of the patients in the ELC group (each P<0.05 as determined by log-rank test). (D-G) Several survival rates of the two patient subgroups in the (D and E) KFSYSCC and (F and G) TCGA cohorts.

    Article Snippet: The samples were stained with anti-HSPD1 (#12165S), poly(ADP-ribose) polymerase (PARP; #9542S) and caspase-3 (#9662S) antibodies from Cell Signaling Technology, Inc. (Danvers, MA, USA), EHMT2 (CSB-PA007497GA01HU) antibodies from Cusabio and ACTB (SC-47778) antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), at 4°C (overnight).

    Techniques: Expressing

    Gene expression pattern of the EHMT2 signature and its association with molecular features in the TCGA cohort (n=817). Histological and molecular subtypes of breast cancer displayed according to the patient clusters divided by EHMT2 signature. * P-value was obtained by an χ 2 test and the remaining P-values were obtained by Fisher’s exact tests.

    Journal: International Journal of Oncology

    Article Title: The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer

    doi: 10.3892/ijo.2018.4608

    Figure Lengend Snippet: Gene expression pattern of the EHMT2 signature and its association with molecular features in the TCGA cohort (n=817). Histological and molecular subtypes of breast cancer displayed according to the patient clusters divided by EHMT2 signature. * P-value was obtained by an χ 2 test and the remaining P-values were obtained by Fisher’s exact tests.

    Article Snippet: The samples were stained with anti-HSPD1 (#12165S), poly(ADP-ribose) polymerase (PARP; #9542S) and caspase-3 (#9662S) antibodies from Cell Signaling Technology, Inc. (Danvers, MA, USA), EHMT2 (CSB-PA007497GA01HU) antibodies from Cusabio and ACTB (SC-47778) antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), at 4°C (overnight).

    Techniques: Expressing

    Univariate and multivariate Cox regression analysis of overall survival in breast cancer (combined with the UNC500 and KFSYSCC cohorts).

    Journal: International Journal of Oncology

    Article Title: The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer

    doi: 10.3892/ijo.2018.4608

    Figure Lengend Snippet: Univariate and multivariate Cox regression analysis of overall survival in breast cancer (combined with the UNC500 and KFSYSCC cohorts).

    Article Snippet: The samples were stained with anti-HSPD1 (#12165S), poly(ADP-ribose) polymerase (PARP; #9542S) and caspase-3 (#9662S) antibodies from Cell Signaling Technology, Inc. (Danvers, MA, USA), EHMT2 (CSB-PA007497GA01HU) antibodies from Cusabio and ACTB (SC-47778) antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), at 4°C (overnight).

    Techniques:

    Association between EHMT2 and HSPD1 in the breast cancer (BRC) clinical cohorts. (A) Comparison of expression levels between the patients in the EHC and ELC groups. A two-group box plot comparing the expression levels of EHMT2 and HSPD1 in EHC and ELC patients is illustrated. P-values were obtained by two-sample t-tests between the EHC and ELC subgroups. The r value indicates the correlation coefficient value of the gene compared with the EHC and ELC subgroup categories. (B) Gene-to-gene networks of EHMT2 and HSPD1 associated with BRC prognosis. Up- and downregulated genes in the high-EHMT2 cluster (EHC) group are indicated in red and green, respectively. The intensity of the color is indicative of the degree of over- or under-expression. Each line and arrow represent functional and physical interactions between the genes and the direction of regulation reported in the literature, respectively. (C) Schematic summary of the effects of EHMT2 on breast cancer.

    Journal: International Journal of Oncology

    Article Title: The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer

    doi: 10.3892/ijo.2018.4608

    Figure Lengend Snippet: Association between EHMT2 and HSPD1 in the breast cancer (BRC) clinical cohorts. (A) Comparison of expression levels between the patients in the EHC and ELC groups. A two-group box plot comparing the expression levels of EHMT2 and HSPD1 in EHC and ELC patients is illustrated. P-values were obtained by two-sample t-tests between the EHC and ELC subgroups. The r value indicates the correlation coefficient value of the gene compared with the EHC and ELC subgroup categories. (B) Gene-to-gene networks of EHMT2 and HSPD1 associated with BRC prognosis. Up- and downregulated genes in the high-EHMT2 cluster (EHC) group are indicated in red and green, respectively. The intensity of the color is indicative of the degree of over- or under-expression. Each line and arrow represent functional and physical interactions between the genes and the direction of regulation reported in the literature, respectively. (C) Schematic summary of the effects of EHMT2 on breast cancer.

    Article Snippet: The samples were stained with anti-HSPD1 (#12165S), poly(ADP-ribose) polymerase (PARP; #9542S) and caspase-3 (#9662S) antibodies from Cell Signaling Technology, Inc. (Danvers, MA, USA), EHMT2 (CSB-PA007497GA01HU) antibodies from Cusabio and ACTB (SC-47778) antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), at 4°C (overnight).

    Techniques: Expressing, Functional Assay